Whois & Analysis for brilinta.com

Ticagrelor (trade name Brilinta, Brilique, and Possia) is a platelet aggregation inhibitor produced by AstraZeneca.

An antiplatelet drug (antiaggregant) is a member of a class of pharmaceuticals that decrease platelet aggregation and inhibit thrombus formation.

They are effective in the arterial circulation, where anticoagulants have little effect.

Myocardial infarction (MI) or acute myocardial infarction (AMI), commonly known as a heart attack, occurs when blood flow stops to a part of the heart causing damage to the heart muscle.

The most common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck, or jaw.

Often it is in the center or left side of the chest and lasts for more than a few minutes.

The discomfort may occasionally feel like heartburn.

Other symptoms may include shortness of breath, nausea, feeling faint, a cold sweat, or feeling tired.

About 30% of people have atypical symptoms, with women more likely than men to present atypically.

Among those over 75 years old, about 5% have had an MI with little or no history of symptoms.

An MI may cause heart failure, an irregular heartbeat (including serious types), cardiogenic shock, or cardiac arrest.

Adenosine monophosphate (AMP), also known as 5'-adenylic acid, is a nucleotide that is used as a monomer in RNA.

It is an ester of phosphoric acid and the nucleoside adenosine, which does not have the typical high energy bond of the so called adenosine monophosphate ("AMP") that arises on the hydrolysis of ATP.

AMP consists of a phosphate group, the sugar ribose, and the nucleobase adenine.

As a substituent it takes the form of the prefix adenylyl-.

A tablet is a pharmaceutical dosage form.

Tablets may be defined as the solid unit dosage form of medicament or medicaments with or without suitable excipients and prepared either by molding or by compression.

It comprises a mixture of active substances and excipients, usually in powder form, pressed or compacted from a powder into a solid dose.

The excipients can include diluents, binders or granulating agents, glidants (flow aids) and lubricants to ensure efficient tabletting; disintegrants to promote tablet break-up in the digestive tract; sweeteners or flavours to enhance taste; and pigments to make the tablets visually attractive or aid in visual.

A polymer coating is often applied to make the tablet smoother and easier to swallow, to control the release rate of the active ingredient, to make it more resistant to the environment (extending its shelf life), or to enhance the tablet's appearance.